A Study to Investigate the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants With Resistant Hypertension

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 218 participants.

Also called NCT06168409

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 218 participants (enrolled count) (from the registry)
Sponsor
  • AstraZeneca Registry lists this organization as the lead sponsor
Registry
  • NCT NCT06168409
  • EU CT 2023-507640-36-00
Other papers using this trial's data
  • Effect of baxdrostat on ambulatory blood pressure in patients with resistant hypertension (Bax24): a phase 3, randomised, double-blind, placebo-controlled trial Lancet (London, England), 2026-03-07 DOI, PubMed 41794437

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Australia, Belgium, Bulgaria, Canada, Czechia, Germany, Greece, Hungary, Malaysia, Philippines, Poland, Saudi Arabia, Slovakia, South Africa, Spain, Taiwan, Thailand, Türkiye, United Kingdom, Vietnam (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06168409. Randomized; quadruple masking; primary purpose treatment. Start 2024-03-01 (actual); primary completion 2025-08-17 (actual). Results posted on 2026-08-06.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Investigate the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants With Resistant Hypertension
Acronym
Bax24
Condition
Resistant Hypertension
Intervention (Drug)
Baxdrostat
Intervention (Drug)
Placebo
Lead sponsor
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct06168409
Content hash
f118642c112c4bdd1d2441defcbea2fe4b26d4fc3dda9088690de1de0d3f24ff